Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection

References

• Anon. INTELENCE™ (etravirine) Tablets. Raritan NJ: Tibotec Therapeutics, Division of Ortho Biotech Products L.P. 2008.
   Google Scholar
• UNAIDS (the Joint United Nations Programme on HIV/AIDS). AIDS epidemic update: December 2007. Available at: http://www.google.co.uk/search?hl=en&q=UNAIDS.+AIDS+epidemic+update+%3A+December+2007&btnG=Search&meta=
   Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Losina E, Yazdanpanah Y, Duffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d’Ivoire. Antivir Ther. 2007:12;543–551.
   Google Scholar
• Bezemer D, Jurriaans S, Prins M, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. Aids. 2004;18:1571–1577.
   PubMed Web of Science ®Google Scholar
• Yerly S, von WV, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. Aids. 2007;21:2223–2229.
   PubMed Web of Science ®Google Scholar
• SP (SPREAD Programme). Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008;22:625–630.
   Google Scholar
• Vercauteren J, Deforche K, Theys K, et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in Portugal. Retrovirology. 2008;5:12.
   PubMed Web of Science ®Google Scholar
• Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr. 2005;40:505–511.
   PubMed Web of Science ®Google Scholar
• Chaix ML, Desquilbet L, Descamps D, et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther. 2007;12:1305–1310.
   PubMed Web of Science ®Google Scholar
• Poggensee G, Kucherer C, Werning J, et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med. 2007;8:511–519.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo G, et al; for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106.
   PubMed Web of Science ®Google Scholar
• Clotet B. Efavirenz: resistance and cross-resistance. Int J Clin Pract Suppl. 1999;103:21–25.
   PubMedGoogle Scholar
• Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol. 2001;65:445–458.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339–347.
   PubMed Web of Science ®Google Scholar
• Koval CE, Dykes C, Wang J, Demeter LM. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology. 2006;353:184–192.
   PubMed Web of Science ®Google Scholar
• Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with highlevel resistance to protease inhibitors. J Virol. 1997;71:1089–1096.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol. 1998;72:3773–3778.
   PubMed Web of Science ®Google Scholar
• Picchio GR, Valdez H, Sabbe R, et al. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr. 2000;25:289–295.
   PubMed Web of Science ®Google Scholar
• Prado JG, Franco S, Matamoros T, et al. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology. 2004;326:103–112.
   PubMed Web of Science ®Google Scholar
• Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther. 2004;2:147–151.
   PubMedGoogle Scholar
• Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. Aids. 2006; 20:995–1002.
   PubMed Web of Science ®Google Scholar
• Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192:24–29.
   PubMed Web of Science ®Google Scholar
• Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42:610–613.
   PubMed Web of Science ®Google Scholar
• Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007; 195:711–715.
   PubMed Web of Science ®Google Scholar
• Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. 15th Con Retrovir Opportun Infect, Boston. 2008. Abstract 792.
   Google Scholar
• Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44:591–595.
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466–474.
   PubMed Web of Science ®Google Scholar
• Saag M, Prudence I, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV-1: Week 48 results of the MERIT study. 4th IAS Conference Sydney, Australia. 2007. Abstract WESS104.
   Google Scholar
• Westby M, Lewis M, Whitcomb, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909–4920.
   PubMed Web of Science ®Google Scholar
• Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl 1):38–46.
   PubMedGoogle Scholar
• Cooper DA, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conf Retro Opportun Infect Los Angeles. 2007. Abstract 105aLB.
   Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261–1269.
   PubMed Web of Science ®Google Scholar
• Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conf Retro Opportun Infect Los Angeles, CA. 2007. Abstract 105bLB.
   Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35:1657–1663.
   PubMed Web of Science ®Google Scholar
• Anon. ISENTRESS™ Tablets (package insert). Whitehouse Station NJ: Merck & Co, 2007.
   Google Scholar
• Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680–4686.
   PubMed Web of Science ®Google Scholar
• Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47:2550–2560.
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773–12782.
   PubMed Web of Science ®Google Scholar
• Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS. 2003;17: 2487–2494.
   PubMed Web of Science ®Google Scholar
• Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. Aids. 2003;17:F49–F54.
   PubMed Web of Science ®Google Scholar
• Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227. International Congress on Drug Therapy in HIV Infection. Glasgow, UK. 2006a. Abstract PL5.6.
   Google Scholar
• Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis. 2008;47:969–978.
   PubMed Web of Science ®Google Scholar
• Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. Aids. 2007;21:F1–F10.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Scholler-Gyure M, Workman C, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1 -infected patients. Antivir Ther. 2008a; 13:655–661.
   PubMed Web of Science ®Google Scholar
• Woodfall B, De Smedt G, Berckmans C, Baeten B, Peeters M. No frequent reporting of neurological or psychiatric events during TMC125 treatment. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK. 2006b. Abstract 146.
   Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet. 2007;370:29–38.
   PubMed Web of Science ®Google Scholar
• Di Biagio A, Bruzzone B, Rosso R, et al. Successful rescue therapy with raltegravir (MK-0518) and etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs. AIDS Patient Care STDS. 2008;22:355–357.
   PubMed Web of Science ®Google Scholar
• Poveda E, Garrido C, de Mendoza C, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;60:1409–1410.
   PubMed Web of Science ®Google Scholar
• Lapadula G, Calabresi A, Castelnuovo F, et al. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther. 2008a;13:601–605.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Santos JR, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother. 2008;62:909–913.
   PubMed Web of Science ®Google Scholar
• Lapadula G, Izzo I, Gargiulo F. Updated prevalence of genotypic resistance among HIV-1 positive patients naive to antiretroviral therapy: a single center analysis. J Med Virol. 2008b;80:747–753.
   PubMed Web of Science ®Google Scholar
• Molina JM, Cordoba J, Gil A, Gobernado M. Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study. Rev Esp Quimioter. 2007;20:346–353.
   PubMed Web of Science ®Google Scholar
• Di Vincenzo P, Rusconi S, Adorni F, et al. Prevalence of mutations and determinants of genotypic resistance to Etravirine (TMC125) in a large Italian resistance database (ARCA). 6th European HIV Drug Resistance Workshop, Budapest, Hungary. 2008. Abstract 59.
   Google Scholar
• Vingerhoets J, Clotet B, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials. 11th EACS European AIDS Conference, Madrid, Spain. 2007. Abstract P7.3/05.
   Google Scholar
• Kakuda TN, Scholler-Gyure M, Woodfall BJ, et al. TMC125 in combination with other medications: summary of drug-drug interactions. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland. 2006. Abstract PL5.6. 2006.
   Google Scholar
• Schöller-Gyüre M, Kakuda TN, de Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-volunteers. Br J Clin Pharmacol. 2008a; 66:508–516.
   PubMed Web of Science ®Google Scholar
• Peeters M, Janssen K, Kakuda TN, et al. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother. 2008;42:757–765.
   PubMed Web of Science ®Google Scholar
• Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and costeffectiveness of different highly active antiretroviral therapy regimens in the UK (1996–2002). Int J STD AIDS. 2008;19:297–304.
   PubMed Web of Science ®Google Scholar
• Ruof J, Dusek A, DeSpirito M, Demasi RA. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients. Clin Drug Investig. 2007;27:469–479.
   PubMed Web of Science ®Google Scholar
• Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med. 2006;166:521–528.
   PubMed Web of Science ®Google Scholar
• Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. Aids. 2005;19:815–822.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Bracciale L, Colafigli M, et al. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther. 2007;12:835–839.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370:1923–1928.
   PubMed Web of Science ®Google Scholar
• Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. Aids. 2007;21:825–834.
   PubMed Web of Science ®Google Scholar
• Davis J, Scholler-Gyure M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ritonavir on the steady-state Pharmacokinetics of Oral Maraviroc in Healthy Subjects. 11th European AIDS Conference/ EACSMadrid, Spain. 2007. Abstract P4.3/02.
   Google Scholar
• Schöller M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, CO. 2006. Abstract 583.
   Google Scholar
• Schöller-Gyüre M, Woodfall B, Bollen S, Peeters M, Vandermeulen K, Hoetelmans, R. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125with fosamprenavir/ritonavir. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2006a. San Francisco, CA. Abstract A-370.
   Google Scholar
• Schöller-Gyüre M, Woodfall B, De Marez T, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir. 8th International Congress on Drug Therapy in HIV infection, Glasgow, UK. 2006b. Abstract P278.
   Google Scholar
• Piscitelli SC, Baede P, Van’t Klooster G, Graham N. TMC125 does not alter lopinavir/ritonavir (LPV/RTV) pharmacokinetics in healthy volunteers. 42nd Intersci Conf Antimicrob Agents Chemother San Diego, CA. 2002. Abstract A-1824.
   Google Scholar
• Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIVnegative volunteers. Antivir Ther. 2007;12:789–796.
   PubMed Web of Science ®Google Scholar
• Schöller-Gyüre M, van den BW, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol. 2008b;48:322–329.
   PubMed Web of Science ®Google Scholar
• PE (Panel of Experts). Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. European AIDS Clinical Society (EACS). 2007. Available at: http://www.eacs.eu/guide/index.htm.
   Google Scholar
• Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65–71.
   PubMed Web of Science ®Google Scholar
• PAGAA (Panel on Antiretroviral Guidelines for Adults and Adolescents). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008. Available at: http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&GuidelineID=7.
   Google Scholar
• Kakuda T, Konigs C, Feiterna-Sperling C, et al. Pharmacokinetics of the next-generation NNRTI TMC125 in HIV-infected children between 6 and 17 years of age. 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA. 2008b. Abstract 578.
   Google Scholar